Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential deals, R&D, commercial and market access strategies.
How it helps
With In Vivo, you’ll benefit from:
How it works
Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service.
Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.
Incisive projections of future industry advances
Analysis of trends shaping the market landscape
Access interviews with leading decision makers, industry experts and thought leaders, across the industry.
Put your questions about any of our news stories, data and analysis to our expert journalists and analysts.
What's successful, what are the trends
In Vivo
By William Looney 15 May 2018
On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.
Topic Strategy
In Vivo
11 May 2018
Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise?In Vivotalks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value. (3) Work fast – spend forward. (4) Reach out earn the business.
Topic BioPharmaceutical
In Vivo
By Ashley Yeo 11 May 2018
Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.
In Vivo
10 May 2018
As events and developments in oncology rapidly shift and unfold, it’s more critical than ever to stay vigilant and agile to stay ahead.Understand these market disruptions and react to them with confidence with the data in Innovation in Oncology, the vital, free infographic from In Vivo.
Topic Cancer
In Vivo
10 May 2018
Looking for your path to success in oncology? Stay on top of the rapidly accelerating complexity of oncology drug development with the crucial insights into cancer treatments that only In Vivo can provide – now yours as a free download.
Topic Cancer
In Vivo
By Ashley Yeo 08 Apr 2018
The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.
Topic Digital Health
In Vivo
By Rachel Laing, Alessia Deglincerti, Mark Ratner 28 Feb 2018
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
In Vivo
By William Looney 08 Dec 2017
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite.
Topic BioPharmaceutical
In Vivo
22 Nov 2017
CAR-T What's Next Approval Webinar Recording, 24 October 2017
In Vivo
By Susan Garfield 01 Nov 2017
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes.
Topic BioPharmaceutical
In Vivo
By William Looney 04 Oct 2017
Trek Therapeutics, a three-year old biotech founded by a group of virology veterans.
Topic BioPharmaceutical
Scrip, In Vivo, Pink Sheet, Medtech Insight
07 Sep 2017
What actually keeps biopharma execs up at night? Take our quiz to find out.
Topic Deal trends Diseases Drug development landscape FDA Medtech Personalized Medicine Parkinsons disease Reimbursement
In Vivo
By William Looney 03 Aug 2017
With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners.
Topic Cancer
In Vivo
02 Aug 2017
Oncology Innovation: lots of drugs, lots of trials, sometimes not enough patients.
Topic Cancer
Trialtrove, In Vivo
13 Jul 2017
Imagine a world where you can print out your own medicine at home...
Topic Personalized Medicine
In Vivo
23 May 2018
In Vivo
23 May 2018
In Vivo
21 May 2018
In Vivo
16 May 2018
In Vivo
14 May 2018
In Vivo
14 May 2018
In Vivo
09 May 2018
In Vivo
09 May 2018
In Vivo
07 May 2018
In Vivo
02 May 2018
In Vivo
25 Apr 2018
In Vivo
25 Apr 2018
In Vivo
23 Apr 2018
In Vivo
23 Apr 2018
In Vivo
23 Apr 2018
UK
USA
Connecticut, USA
Amanda specializes in
+18 year(s) experience
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
